Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.51 |
| ▸ | BCL9 | O00512 | 1/20 | 0.50 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 9/20 | 0.47 |
| ▸ | F10 | P00742 | 1/20 | 0.46 |
| ▸ | CTSC | P53634 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | KIT | P10721 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31258409 | 0.79 | ROCK2 (0.52) | BCL9CTNNB1ROCK2KITROCK1 | |
| SCHEMBL2450367 | 0.78 | HTR2C (0.56) | HTR2CALDH1A1SMN1; SMN2USP2HPGD | |
| SCHEMBL29542019 | 0.78 | HTR2C (0.53) | HTR2CALDH1A1SMN1; SMN2USP2HPGD | |
| SCHEMBL2444405 | 0.78 | ALDH1A1 (0.70) | HTR2CF10ALDH1A1SMN1; SMN2USP2 | |
| SCHEMBL4434645 | 0.78 | ALDH1A1 (0.70) | HTR2CF10ALDH1A1SMN1; SMN2USP2 | |
| SCHEMBL2447403 | 0.78 | ALDH1A1 (0.73) | HTR2CALDH1A1SMN1; SMN2 | |
| SCHEMBL24873100 | 0.78 | REN (0.53) | BCL9CTNNB1ROCK2 | |
| SCHEMBL31258387 | 0.78 | REN (0.53) | BCL9CTNNB1ROCK2 | |
| SCHEMBL5049861 | 0.76 | ALDH1A1 (0.53) | HTR2CROCK2F10ALDH1A1SMN1; SMN2 | |
| SCHEMBL6861732 | 0.75 | HTR2C (0.62) | HTR2CALDH1A1SMN1; SMN2USP2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240391896-A1 | SMALL MOLECULE COMPOUND TARGETING BCL9/BETA-CATENIN INTERACTION | Nantong Jutai Biotech Co., Ltd. (CN) | 2024-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240391896-A1 | SMALL MOLECULE COMPOUND TARGETING BCL9/BETA-CATENIN INTERACTION | BCL9, BCL9L, BCL2L11 | HTR2C 4431/4885BCL9 1/4885CTNNB1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.